1Breedveld FC,Weisman MH,Kavanaugh AF,et al.The PREMIER study:A multicenter,randomized,double-blind clinical trial of combination therapy with adalimurnab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early,aggressive rheumatoid arthritis who had not had previous methotrexatc treatment.Arthritis Rheum,2006,54:26.
2Van der Kooij SM,le Cessie S,Goekoop-Ruiterman YP,et al.Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rhcumatoid arthritis.Ann Rheum Dis,2009,68:1153.
3Smolen JS,Kay J,Doyle MK,et al.Golimumab in patients with active rheumatoid arthritis after treatment with turnout necrosis factor alpha inhibitors (CO-AFTER study):a multicentre,randomised,double-blind,placebo-controlled,phase Ⅲ trial.Lancet,2009,374:210.
4Kay J,Matteson EL,Dasgupta B,et al.Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate:a randomized,doubleblind,placebo-controlled,doseranging study.Arthritis Rheum,2008,58:964.
5Keystone E,Heijde D,Mason D Jr,et al.Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis:findings of afifty-two-week,phase Ⅲ,multicenter,randomized,doubleblind,placebo-controlled,parallel-group study.Arthritis Rheum,2008,58:3319.
6Fleischmann R,Vencovsky J,van Vollenhoven RF,et al.Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy:the FAST4WARD study.Ann Rheum Dis,2009,68:805.
7Combe B,Codreanu C,Fiocco U,et al.Efficacy,safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanereept alone in patients with rheumatoid arthritis:a double-blind randomised 2-year study.Ann Rheum Dis,2009,68:1146.
8Mertens M,Singh JA.Anakinra for rheumatoid arthritis:a systematic review.J Rheumatol,2009,36:1118.
9Emery P,Keystone E,Tony HP,et al.IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumout necrosis factor biologicals:results from a 24-week multicentre randomised placebo controlled trial.Ann Rheum Dis,2008,67:1516.
10Tak PP,Rigby WF,Rubbert-Roth A,et al.Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis:the IMAGE trial.Ann Rheum Dis,2010,Oct 11.[Epub ahead of print].
